Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Pharmaceutical company updates 2005 first half milestones
February 10th, 2005
Novavax, Inc., (NASDAQ:NVAX) updated the market on its expected milestones for the first half of 2005 and the milestone achievements of 2004. Novavax reaffirmed its business strategy to build sales of ESTRASORB, its topical estrogen therapy product, to advance current discussions with strategic business partners and to move forward with new drugs and vaccines in its research pipeline. "Fiscal 2004 will prove to have been a pivotal year for Novavax. The 2004 achievements, including a strengthened leadership team, a refocused research and developmenr product pipeline, the King Pharmaceutical transaction to reacquire all rights to ESTRASORB, debt...
Source: Women's Health Weekly (2005-02-10)
|
